Search results
Results from the WOW.Com Content Network
Arsphenamine, also known as Salvarsan or compound 606, is an antibiotic drug that was introduced at the beginning of the 1910s as the first effective treatment for the deadly infectious diseases syphilis, relapsing fever, and African trypanosomiasis. [2] [3] This organoarsenic compound was the first modern antimicrobial agent. [4]
1911 – Arsphenamine, also Salvarsan [1] 1912 – Neosalvarsan; 1935 – Prontosil (an oral precursor to sulfanilamide), the first sulfonamide; 1936 – Sulfanilamide; 1938 – Sulfapyridine (M&B 693) 1939 – sulfacetamide; 1940 – sulfamethizole; 1942 – benzylpenicillin, the first penicillin; 1942 – gramicidin S, the first peptide ...
Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form, "Neosalvarsan" (Compound 914), was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century. [7]
Therefore, Hata's and Ehrlich's work represents a turning point for experimental and therapeutic pharmacology and paved the way for the development of antibiotics decades later. [4] Salvarsan was established as the standard treatment for syphilis until it was replaced by the antibiotic penicillin after World War II, which has fewer adverse side ...
Manufactured by Hoechst AG, Salvarsan became the most widely prescribed drug in the world. It was the most effective drug for treating syphilis until penicillin became available in the 1940s. [ 19 ] Salvarsan required improvement as to side effects and solubility and was replaced in 1911 with Neosalvarsan .
Paul Ehrlich is a physician working in a German hospital. He is dismissed for his constant disregard for hospital rules, which are bound by bureaucratic red tape.The reason for his conflict is his steadily rising interest in research for selective color staining, the marking of cells and microorganisms using certain dyes and marking agents which have a certain 'affinity' for their target and ...
Both Salvarsan and Neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. [1] This scheme is the basis for most modern pharmaceutical research.
The Quiet Duel was released on DVD in the U.S. by BCI Eclipse, as the first title in their "Director's Series". It was never released in U.K. cinemas, but was released on DVD in the U.K. in 2006 under the title "The Silent Duel".